Sirtex Medical receives AUD$1.9bn takeover offer from CDH Investments

By Thierry Boudan

Leading Australian medical company Sirtex Medical has announced that it has received a AUD$1.87bn (US$1.41bn) takeover offer from Chinese company CDH Investments.

The offer from CDH would see the Chinese firm paying AUD$33.6 per share for the liver cancer treatment specialist, equating to a 20.6% premium to the company’s unaffected share price.

See also:

The news puts pressure on cancer treatment company Varian’s existing takeover attempt, with its own offer made in January standing at AUD$310mn less than CDH’s new offer.

However, statements from both Sirtex and Varian suggest that the Australian firm will continue to pursue the existing takeover arrangement, despite the higher offer from CDH.

“At this time, the directors of Sirtex continue to believe the existing scheme of arrangement with Varian is in the best interests of Sirtex shareholders and continue to unanimously support and recommend the Scheme,” Sirtex said.

“The Varian Scheme has been unanimously approved by both boards of directors, has fully committed financing and has received all necessary regulatory approvals. We believe the Varian Scheme offers more value and carries far less risk for Sirtex stockholders,” Varian said.

Sirtex also revealed that a takeover by CDH would need approval of Australia’s Foreign Investment Review Board.

Share

Featured Articles

Twitter timeline – how Musk pulled off a hostile takeover

Elon Musk strikes deal to buy Twitter for US$44bn following four months of cryptic tweets, secret meetings and buying of shares – here’s the timeline

Top 10 Asia restaurants, from Tokyo’s Den to Bangkok’s Sorn

From Tokyo to Bangkok, with cuisines spanning Cantonese, Thai and German, we highlight Asia’s top 10 places to eat, as per Asia’s 50 Best Restaurants

Microsoft: what Asia leaders need to know about hybrid work

Microsoft’s 2022 Work Trend Index guides Asia leaders to navigating a hybrid future – from making the office worth the commute to rebuilding social capital

Meet the company: EV Nio to list in Hong Kong, enter Europe

Leadership & Strategy

12 Tech trends to watch closely in 2022, from CB Insights

Technology

Why Deloitte Australia’s HR technology is winning awards

Human Capital